Good Therapeutics raises $11M to develop ‘context dependent’ protein drugs

Good Therapeutics CEO John Mulligan. (Good Therapeutics Photo)

Seattle biotech startup Good Therapeutics raised another $11 million to create “context dependent” protein drugs that act only when needed.

The 4-year-old company is developing cytokines that regulate their own activity in response to biomarkers and metabolic signals, said

This post was originally published on this site


Check out
%d bloggers like this: